Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2020-11-05 Capital/Financing Update
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Madrigal Pharmaceuticals, Inc. It registers additional shares under the company's Amended 2015 Stock Plan. The text includes details about the securities to be registered, incorporation by reference of prior filings, exhibits, and signatures. Form S-8 is a registration statement used to register securities to be offered to employees under employee benefit plans. This is a capital markets filing related to share registration and stock plans, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement document. Therefore, the filing type corresponds to a capital/financing update related to securities registration under the Securities Act of 1933.
2020-11-05 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details a $200 million at-the-market offering of common stock, including terms of the sales agreement with Cowen and Company, LLC, risk factors, use of proceeds, and other offering details. The document is a registration and offering prospectus supplement, which is a capital raising document. It is not a financial report, earnings release, management discussion, or any other report type. It is an update on capital raising activities and financing terms. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the document as a prospectus supplement related to a stock offering.
2020-11-05 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 5, 2020, reporting the entry into a material definitive agreement, specifically a Sales Agreement for an 'at the market' (ATM) offering of common stock. The content focuses on the description of the financing agreement and related legal opinions. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The document is a current report announcing a capital raising agreement and related financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 5594 characters, which is sufficient to contain substantive information about the financing agreement rather than just a brief announcement. Hence, the classification is CAP with high confidence.
2020-11-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions that the company issued a press release announcing financial results for the fiscal quarter ended September 30, 2020, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length is 3670 characters, which is relatively short and consistent with a current report announcing an earnings release. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2020-11-05 English
10-Q
Interim / Quarterly Report Q3 2020
2020-11-05 English
SC 13D/A
Major Shareholding Notification
2020-09-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.